These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 10406693)

  • 1. Antiproliferative stent coatings: Taxol and related compounds.
    Herdeg C; Oberhoff M; Karsch KR
    Semin Interv Cardiol; 1998; 3(3-4):197-9. PubMed ID: 10406693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-eluting stent: the emerging technique for the prevention of restenosis.
    Sheiban I; Carrieri L; Catuzzo B; Destefanis P; Oliaro E; Moretti C; Trevi GP
    Minerva Cardioangiol; 2002 Oct; 50(5):443-53. PubMed ID: 12384626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-eluting stents.
    Chieffo A; Colombo A
    Minerva Cardioangiol; 2002 Oct; 50(5):419-29. PubMed ID: 12384624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple-coated stents (Hirudin/Iloprost/Paclitaxel): an in vitro approach for characterizing the antiproliferative potential of each individual compound.
    Voisard R; Stemberger A; Baur R; Herter T; Hähnel I; Resch A; Seliger C; Hemmer W; Hannekum A; Hombach V; Alt E
    Int J Cardiol; 2005 Jul; 102(3):425-33. PubMed ID: 16004887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus. Implications for local drug delivery.
    Wessely R; Blaich B; Belaiba RS; Merl S; Görlach A; Kastrati A; Schömig A
    Thromb Haemost; 2007 Jun; 97(6):1003-12. PubMed ID: 17549304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Drug-eluting stents do they make the difference? ].
    Presbitero P; Asioli M
    Minerva Cardioangiol; 2002 Oct; 50(5):431-42. PubMed ID: 12384625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arsenic trioxide eluting stent reduces neointima formation in a rabbit iliac artery injury model.
    Yang W; Ge J; Liu H; Zhao K; Liu X; Qu X; Li W; Huang Y; Sun A; Zou Y
    Cardiovasc Res; 2006 Dec; 72(3):483-93. PubMed ID: 17020754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival of endothelial cells in vitro on Paclitaxel-loaded coronary stents.
    Prasad CK; Resmi KR; Krishnan LK; Vaishnav R
    J Biomater Appl; 2005 Apr; 19(4):271-86. PubMed ID: 15788425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term evaluation of paclitaxel-coated stents for treatment of native coronary lesions. First results of both the clinical and angiographic 18 month follow-up of TAXUS I.
    Büllesfeld L; Gerckens U; Müller R; Grube E
    Z Kardiol; 2003 Oct; 92(10):825-32. PubMed ID: 14579046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of paclitaxel and nitric oxide as a novel treatment for the reduction of restenosis.
    Lin CE; Garvey DS; Janero DR; Letts LG; Marek P; Richardson SK; Serebryanik D; Shumway MJ; Tam SW; Trocha AM; Young DV
    J Med Chem; 2004 Apr; 47(9):2276-82. PubMed ID: 15084126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sirolimus- and taxol-eluting stents differ towards intimal hyperplasia and re-endothelialization.
    Liuzzo JP; Ambrose JA; Coppola JT
    J Invasive Cardiol; 2005 Sep; 17(9):497-502. PubMed ID: 16145242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are impaired endothelial progenitor cells involved in the processes of late in-stent thrombosis and re-endothelialization of drug-eluting stents?
    Zhao FH; Chen YD; Jin ZN; Lu SZ
    Med Hypotheses; 2008; 70(3):512-4. PubMed ID: 17764856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [State of treatment of coronary artery disease by drug releasing stents].
    Müller R; Büllesfeld L; Gerckens U; Grube E
    Herz; 2002 Sep; 27(6):508-13. PubMed ID: 12378395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The paclitaxel-eluting stent in percutaneous coronary intervention: part I: background and clinical comparison to bare metal stents.
    Gruchalla KJ; Nawarskas JJ
    Cardiol Rev; 2006; 14(2):88-98. PubMed ID: 16493246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of cytochalasin D-eluting stents on intimal hyperplasia in a porcine coronary artery model.
    Salu KJ; Bosmans JM; Huang Y; Hendriks M; Verhoeven M; Levels A; Cooper S; De Scheerder IK; Vrints CJ; Bult H
    Cardiovasc Res; 2006 Feb; 69(2):536-44. PubMed ID: 16386237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents.
    Grube E; Buellesfeld L
    Herz; 2004 Mar; 29(2):162-6. PubMed ID: 15054588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss.
    Mehilli J; Kastrati A; Wessely R; Dibra A; Hausleiter J; Jaschke B; Dirschinger J; Schömig A;
    Circulation; 2006 Jan; 113(2):273-9. PubMed ID: 16391155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymer-based paclitaxel-eluting coronary stents. Clinical results in de novo lesions.
    Chieffo A; Colombo A
    Herz; 2004 Mar; 29(2):147-51. PubMed ID: 15054587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-eluting stents: clinical perspectives on drug and design differences.
    Rogers CD
    Rev Cardiovasc Med; 2005; 6 Suppl 1():S3-12. PubMed ID: 15665795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.